FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223641488> ?p ?o ?g. }

• W4223641488 endingPage "837" @default.
• W4223641488 startingPage "837" @default.
• W4223641488 abstract "The non-canonical Wnt signalling receptor ROR1 is aberrantly expressed in numerous cancers, including ovarian and endometrial cancer. We previously reported that silencing ROR1 could inhibit the proliferation and metastatic potential of ovarian and endometrial cancer cells in vitro. Zilovertamab is an ROR1-targeting humanised monoclonal antibody, with demonstrated safety and efficacy in clinical trials of several ROR1-related malignancies. The aim of this study was to investigate the potential of zilovertamab alone, or in combination with commonly utilised gynaecological cancer therapies (cisplatin, paclitaxel and the PARP inhibitor-Olaparib) on high-grade serous ovarian cancer (HGSOC), including models of platinum resistance and homologous recombination deficiency (CaOV3, CaOV3CisR, PEO1 and PEO4) and endometrial cancer (EC) cell lines (Ishikawa and KLE). The effect of zilovertamab (at 25 µg/mL or 50 µg/mL) +/- agents was investigated using the IncuCyte S3 Live Cell imaging system. Zilovertamab alone inhibited the proliferation of HGSOC and EC cells in vitro, including in models of platinum resistance and homologous recombination deficiency. In general, the addition of commonly used chemotherapies to a fixed dose of zilovertamab did not enhance the observed anti-proliferative activity. This study supports the potential of zilovertamab, or other ROR1-targeting therapies, for treating women with HGSOC and EC." @default.
• W4223641488 created "2022-04-15" @default.
• W4223641488 creator A5035793002 @default.
• W4223641488 creator A5040833433 @default.
• W4223641488 creator A5051055093 @default.
• W4223641488 creator A5059012946 @default.
• W4223641488 creator A5073716197 @default.
• W4223641488 creator A5077578026 @default.
• W4223641488 date "2022-04-11" @default.
• W4223641488 modified "2023-09-30" @default.
• W4223641488 title "The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells" @default.
• W4223641488 cites W1964081206 @default.
• W4223641488 cites W1973268287 @default.
• W4223641488 cites W1975711182 @default.
• W4223641488 cites W1983054966 @default.
• W4223641488 cites W2063011414 @default.
• W4223641488 cites W2075752480 @default.
• W4223641488 cites W2086297371 @default.
• W4223641488 cites W2092864627 @default.
• W4223641488 cites W2099540110 @default.
• W4223641488 cites W2142658272 @default.
• W4223641488 cites W2153806783 @default.
• W4223641488 cites W2169249953 @default.
• W4223641488 cites W2416824063 @default.
• W4223641488 cites W2559064918 @default.
• W4223641488 cites W2593869804 @default.
• W4223641488 cites W2602494391 @default.
• W4223641488 cites W2761228804 @default.
• W4223641488 cites W2770576214 @default.
• W4223641488 cites W2787147590 @default.
• W4223641488 cites W2806532541 @default.
• W4223641488 cites W2884186787 @default.
• W4223641488 cites W2911082000 @default.
• W4223641488 cites W2955333028 @default.
• W4223641488 cites W3030284169 @default.
• W4223641488 cites W3049271086 @default.
• W4223641488 cites W3097111364 @default.
• W4223641488 cites W3198543540 @default.
• W4223641488 cites W3205092450 @default.
• W4223641488 doi "https://doi.org/10.3390/pharmaceutics14040837" @default.
• W4223641488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35456672" @default.
• W4223641488 hasPublicationYear "2022" @default.
• W4223641488 type Work @default.
• W4223641488 citedByCount "6" @default.
• W4223641488 countsByYear W42236414882023 @default.
• W4223641488 crossrefType "journal-article" @default.
• W4223641488 hasAuthorship W4223641488A5035793002 @default.
• W4223641488 hasAuthorship W4223641488A5040833433 @default.
• W4223641488 hasAuthorship W4223641488A5051055093 @default.
• W4223641488 hasAuthorship W4223641488A5059012946 @default.
• W4223641488 hasAuthorship W4223641488A5073716197 @default.
• W4223641488 hasAuthorship W4223641488A5077578026 @default.
• W4223641488 hasBestOaLocation W42236414881 @default.
• W4223641488 hasConcept C104317684 @default.
• W4223641488 hasConcept C121608353 @default.
• W4223641488 hasConcept C126322002 @default.
• W4223641488 hasConcept C159654299 @default.
• W4223641488 hasConcept C182979987 @default.
• W4223641488 hasConcept C203014093 @default.
• W4223641488 hasConcept C2776694085 @default.
• W4223641488 hasConcept C2777088508 @default.
• W4223641488 hasConcept C2777292972 @default.
• W4223641488 hasConcept C2778239845 @default.
• W4223641488 hasConcept C2779962180 @default.
• W4223641488 hasConcept C2780427987 @default.
• W4223641488 hasConcept C502942594 @default.
• W4223641488 hasConcept C542903549 @default.
• W4223641488 hasConcept C54355233 @default.
• W4223641488 hasConcept C55493867 @default.
• W4223641488 hasConcept C62112901 @default.
• W4223641488 hasConcept C71924100 @default.
• W4223641488 hasConcept C82381507 @default.
• W4223641488 hasConcept C86803240 @default.
• W4223641488 hasConcept C96232424 @default.
• W4223641488 hasConcept C98274493 @default.
• W4223641488 hasConceptScore W4223641488C104317684 @default.
• W4223641488 hasConceptScore W4223641488C121608353 @default.
• W4223641488 hasConceptScore W4223641488C126322002 @default.
• W4223641488 hasConceptScore W4223641488C159654299 @default.
• W4223641488 hasConceptScore W4223641488C182979987 @default.
• W4223641488 hasConceptScore W4223641488C203014093 @default.
• W4223641488 hasConceptScore W4223641488C2776694085 @default.
• W4223641488 hasConceptScore W4223641488C2777088508 @default.
• W4223641488 hasConceptScore W4223641488C2777292972 @default.
• W4223641488 hasConceptScore W4223641488C2778239845 @default.
• W4223641488 hasConceptScore W4223641488C2779962180 @default.
• W4223641488 hasConceptScore W4223641488C2780427987 @default.
• W4223641488 hasConceptScore W4223641488C502942594 @default.
• W4223641488 hasConceptScore W4223641488C542903549 @default.
• W4223641488 hasConceptScore W4223641488C54355233 @default.
• W4223641488 hasConceptScore W4223641488C55493867 @default.
• W4223641488 hasConceptScore W4223641488C62112901 @default.
• W4223641488 hasConceptScore W4223641488C71924100 @default.
• W4223641488 hasConceptScore W4223641488C82381507 @default.
• W4223641488 hasConceptScore W4223641488C86803240 @default.
• W4223641488 hasConceptScore W4223641488C96232424 @default.
• W4223641488 hasConceptScore W4223641488C98274493 @default.
• W4223641488 hasIssue "4" @default.

• next